Introduction
Maturity-onset diabetes of the young (MODY) is initially misdiagnosed as type 1 or type 2 diabetes in approximately 80% of cases, resulting in inappropriate treatment and follow up. [1] [2] [3] [4] [5] [6] [7] MODY is characterised by three key features: (1) diabetes typically diagnosed <25 years of age in at least one family member; (2) autosomal dominant inheritance (with diabetes in a parent or child); and (3) noninsulin dependent diabetes (or evidence of significant endogenous insulin production more than three years post diagnosis). 8 However, the significance of these features may not be appreciated by health care professionals, leading to incorrect diagnosis and treatment. Poor recognition results in mean delays of more than nine years from diabetes diagnosis to specific molecular genetic diagnosis, in many cases leading to years of unnecessary insulin treatment. 9 Early diagnosis of MODY is important as transfer from insulin to sulphonylurea is less likely to be successful with increasing duration of diabetes. 10 Biomarker tests (islet autoantibodies and C-peptide) can help identify appropriate candidates for genetic testing for MODY, or other forms of monogenic diabetes, avoiding reliance on clinical recognition. 11, 12 As these tests are not routinely used in clinical practice, identifying individuals diagnosed with diabetes below the age of 25 years with an affected parent or child may be a useful first step in detecting some of those in whom further testing may be warranted (Table 1) . However, islet autoantibody and C-peptide tests are cheap and easily available and can aid differential diagnosis. [11] [12] [13] [14] The free online MODY probability calculator or Diabetes Diagnostics app can also be used to identify those with a higher probability of having MODY (www. diabetesgenes.org/content/modyprobability-calculator). 15 
Islet autoantibodies
Type 1 diabetes results from an autoimmune mediated destruction of the insulin-producing pancreatic beta cells. Autoantibodies recognising the islet cell antigens glutamic acid decarboxylase (GAD65), insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) are present in up to 90% of newly-diagnosed patients with type 1 diabetes. 16 Most individuals with type 1 diabetes will have multiple islet autoantibodies detectable in their blood at diagnosis and less than 10% will have only one detectable antibody when assessed in combination. 11 Testing islet autoantibodies could be considered the most helpful investigation to differentiate type 1 diabetes from MODY. 11 The prevalence of GAD, IA-2 and ZnT8 autoantibodies is less than 1% in GCK, HNF1A and HNF4A MODY, and testing close to diagnosis gives very good discrimination of type 1 diabetes from MODY. 11 The difference in prevalence of autoantibodies between type 1 diabetes and MODY means these tests are useful in aiding differential diagnosis and identifying patients who may benefit from genetic testing. Although antibody testing close to diagnosis is recommended, GAD and IA-2 remain detectable for many years and show high levels of diagnostic accuracy. 17 Testing multiple antibodies is important as multiple antibody positivity increases the certainty of type 1 diabetes and significantly increases the proportion of patients with a detectable antibody from approximately 60% with GAD only to over 80% with GAD and IA-2. 11 ICA (islet cell autoantibodies) testing was the first method for
Tests aiding diagnosis of monogenic diabetes

Vignette
Daniel was diagnosed with diabetes at the age of 21. He was slim with a BMI of 20kg/m 2 , presenting blood glucose was 15mmol/L, HbA1c was 68mmol/mol (8.4%), and he reported symptoms of polyuria, polydipsia, nocturia and lethargy. He was given a diagnosis of type 1 diabetes and was started immediately on basal bolus insulin. His mother was diagnosed with type 1 diabetes at 26 years of age and she had always been insulin treated. His maternal grandfather, who was slim, was diagnosed with type 2 diabetes in his 40s and was treated with metformin.
It was seven years later, when Daniel moved to another area, that his local genetic diabetes nurse questioned his diagnosis of type 1 diabetes. This was due to the autosomal dominant family history of diabetes and the fact that he remained on small doses of insulin (0.3u/kg/day) with good glycaemic control (HbA1c 48mmol/mmol; 6.5%) despite admitting to omitting insulin on some occasions. His details were entered into the MODY probability calculator (www.diabetesgenes.org/content/mody-probability-calculator) which indicated a 1 in 13 chance of Daniel having maturity-onset diabetes of the young (MODY). This reflected an increased chance compared to the background prevalence of 1 in 143. As identifying a genetic diagnosis could potentially change Daniel's treatment, further tests were undertaken.
Islet autoantibodies to glutamate decarboxylase (GAD) and islet antigen-2 (IA-2) antibodies and zinc transporter 8 (ZnT8) were tested and were all negative, increasing the suspicion that his diabetes may have a non-autoimmune cause. His urinary C-peptide creatinine ratio (UCPCR) seven years post diagnosis was 1.70nmol/mol, indicating that Daniel was continuing to make significant endogenous insulin which would not be expected in longstanding type 1 diabetes. As a consequence of the UCPCR positivity, antibody negativity and dominant family history, genetic testing was undertaken. A heterozygous mutation in HNF1A was identified and a diagnosis of HNF1A MODY was confirmed in Daniel.
Comment. This correct molecular genetic diagnosis enabled Daniel to stop his insulin treatment and transfer to a low dose of sulphonylurea with improvements in quality of life. Family testing confirmed that both his mother and maternal grandfather were also heterozygous for the HNF1A mutation and therefore also had HNF1A MODY, and this diagnosis enabled them to change onto the most appropriate treatment with improvements in glycaemic control.
COPYRIGHT © 2017 JOHN WILEY & SONS detecting islet autoantibodies. ICA testing identifies the presence of human antibodies that bind to rodent or monkey pancreatic tissue; however, the test is non-standardised and the sensitivity can be as low as ~10% (i.e. nine out of 10 people with type 1 diabetes have a negative result); islet cell autoantibodies also disappear rapidly after diagnosis. ICA testing has now mostly been abandoned because of poor diagnostic accuracy; islet cell autoantibodies have low reproducibility, disappear rapidly after diagnosis 18 and are not recommended. IAA (insulin autoantibodies) also have a lower sensitivity and as soon as exogenous insulin is given this is no longer a useful test. Therefore, we recommend testing GAD, IA-2 and ZnT8 in combination. Local laboratories may test for auto antibodies but it is important to establish which tests they offer. (See Appendix 1 available in Practical Diabetes online at www.practicaldiabetes. com for further detail.)
Islet autoantibodies are most useful in enabling a firm diagnosis of type 1 diabetes to be made in those who are antibody positive. This obviates the need for genetic testing as these patients are unlikely to have monogenic diabetes and if two antibodies are positive genetic testing is not indicated. 11 Those previously considered to have type 1 diabetes who are antibody negative should be considered for genetic testing, particularly if they have other features that would raise suspicion of MODY -for example a parent with diabetes or detectable levels of C-peptide.
C-peptide
C-peptide is made in equimolar amounts to insulin and is typically tested in patients on insulin treatment to assess endogenous insulin secretion. Its role in individuals not on insulin treatment is limited. Those with long-standing type 1 diabetes typically have low or undetectable levels (<200pmol/L) indicating insulin deficiency. 12 C-peptide may be present during the honeymoon period in type 1 diabetes so when used to aid differential diagnosis it is best measured at least three years post diagnosis. 19 Historically, C-peptide was considered difficult to measure as it was previously recommended that the blood samples should be collected on ice, centrifuged immediately, and taken to the laboratory within 30 minutes, 20 making the tests impractical within the general clinic setting. However, urinary C-peptide creatinine ratio (UCPCR) is a simple, reliable, non-invasive measure which is stable for three days at room temperature. 12,13 UCPCR can be measured on a postprandial sample taken approximately 2 hours after a meal stimulus, to identify the presence of endogenous insulin. 21 This could either be taken 2 hours after the largest carbohydrate-containing meal of the day and posted from home, or a random non-fasting sample taken at a clinic visit (likely to be post breakfast or post lunch). Samples should be taken in a boric acid tube and may be tested locally, or sent to the Exeter laboratory at the Royal Devon and Exeter NHS Foundation Trust (UCPCR costs <£12). See Table 2 . More recently, it has been shown that plasma C-peptide is more stable than previously thought and there is no degradation within the first 24 hours on whole blood at room temperature when collected on EDTA (ethylene-diamine-tetra-acetic acid). 22 This presents another opportunity for easy and pragmatic assessment of endogenous insulin production on a blood sample collected in primary care or at a routine clinic visit.
If the C-peptide result is 'out of keeping' with other clinical findings, then the test should be repeatedespecially if the result is unexpectedly low. Patients 'tipping out' boric acid preservative from the urine collection tube, or a sample taking more than three days to reach the laboratory, can result in artificially low results. 13 The interpretation of C-peptide levels depends on the specific clinical scenario -i.e. type of diabetes and treatment. However, UCPCR levels <0.2nmol/mmol, or stimulated blood C-peptide <200pmol/L outside the honeymoon period, indicate insulin deficiency which supports a diagnosis of type 1 diabetes. UCPCR ≥0.2nmol/ mol indicates endogenous insulin and has been used to differentiate patients with MODY from type 1 diabetes more than five years post diagnosis. 14 In those with a diabetes duration of more than three years with significant endogenous insulin, an alternative to type 1 diabetes diagnosis should be considered.
Most of the studies of UCPCR have been performed in patients with normal renal function (eGFR >60ml/ min/1.73m 2 ), but it has been validated in patients with type 2 diabetes with moderate renal impairment (eGFR 30-60ml/min/1.73m 2 ). 23 However, the test is not appropriate in patients with severe renal impairment.
MODY probability calculator/ Diabetes Diagnostic app
Prior to genetic testing, clinical details should be entered into the online MODY probability calculator (www.diabetesgenes.org/content/ mody-probability-calculator) to establish the likelihood of MODY in each particular case. This takes into consideration other factors such as parental family history, initial and current treatment, gender, BMI, current age, and age at diagnosis. These tools are for use in patients diagnosed with diabetes under the age of 35 years and were developed on a European Caucasian cohort.
There is no specific recommended probability 'cut off' for proceeding to genetic testing. The current pick-up rate for MODY testing in the UK is 25%, but where a diagnosis would make a difference to a patient's management, testing might still be considered appropriate at a lower probability.
The Diabetes Diagnostics app is available for free download and combines the MODY clinical prediction calculator, information from national and international diabetes guidelines, and expert opinion from world leaders in monogenic diabetes to provide a resource to help guide diabetes classification. The app also includes data regarding other features that may be associated with different causes of monogenic diabetes (e.g. renal cysts). (See Table 3 .)
Genetic testing for MODY
In individuals, previously thought to have type 1 diabetes, diagnosed <25 years of age who are islet autoantibody negative and C-peptide positive more than three years post diagnosis, an alternative diagnosis and genetic testing should be considered.
The molecular genetic laboratory at the Royal Devon and Exeter NHS Foundation Trust carries out genetic testing for all known causes of MODY. EDTA whole blood (ideally 5-10ml) or genomic DNA samples (minimum 5µg) are required and should be sent at room temperature in the post (complying with UN3373 postage requirements: www.un3373.com/info/ regulations/) along with a completed diagnostic request form (available to download at www.diabetesgenes.org/ sites/default/files/mody_request_ form.doc). (Table 2 .) See Appendix 1 available online at www.practical diabetes.com for further detail.
Conclusion
Identifying individuals with monogenic diabetes is essential to ensure they receive optimal treatment. The correct molecular genetic diagnosis also enables follow up of family members and counselling regarding risk to their unaffected children. Non-genetic tests (autoantibodies and C-peptide) should be considered in individuals diagnosed <25 years of age with an affected parent or child. These tests are cheap and org/content/ new-test-allmody-genes GAD = glutamic acid decarboxylase; IA-2 = insulinoma antigen 2; ZnT8 = zinc transporter 8; EDTA = ethylene-diamine-tetra-acetic acid; T1D = type 1 diabetes; T2D = type 2 diabetes; MODY = maturity-onset diabetes of the young; GCK = glucokinase; tNGS = targeted next generation sequencing. Table 3 . Additional features associated with the most common causes of monogenic diabetes
